NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron RevenuesZacks Investment Research • 08/07/26
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/06/26
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesGlobeNewsWire • 08/06/26
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business UpdatesGlobeNewsWire • 07/30/26
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 07/09/26
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR TherapeuticsThe Motley Fool • 07/08/26
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?The Motley Fool • 06/20/26
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock UpZacks Investment Research • 06/16/26
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?Zacks Investment Research • 06/16/26
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling DisorderBenzinga • 06/15/26
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaGlobeNewsWire • 06/13/26
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/10/26
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn'tThe Motley Fool • 06/03/26
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026GlobeNewsWire • 06/01/26
Intellia Therapeutics - Steady Progress, Historic Commercial Approval In SightSeeking Alpha • 05/31/26
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?Zacks Investment Research • 05/27/26
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?Zacks Investment Research • 05/19/26
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/13/26
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in FocusZacks Investment Research • 05/12/26